“We hope to have a clear path for the treatment of this disease,” says Roger Packer, senior vice president of the Center for Neuroscience and Behavioral Medicine.
Yesterday, we hosted the Cure Group 4 Medulloblastoma Consortium in our Research Innovation Campus. This is an international gathering of hand-picked renown researchers and physician scientists in the field looking to discover new therapeutic approaches to treat the most common subtype of medulloblastoma – the most common of childhood malignant brain tumors.
The consortium, led by Dr. Packer and launched in the spring of 2021 through the visionary support and leadership of international philanthropist, Fernando Goldsztein, Founder of the Medulloblastoma Initiative(http://mbinitiative.org/), is uniquely positioned, bringing the expertise of international renown labs, including The Hospital for Sick Children, Sanford Burnham Prebys, Hopp Children’s Cancer Center Heidelberg, Michigan Medicine and Emory University.
Leaders in field are looking for novel ways of treating the disease within a 12–18-month period by combining expertise of understanding the biology of tumor with new novel forms of therapy (such as molecular based therapy and immunotherapy). Together, they will share data, work synergistically and expedite the development of ways for treatment. #innovation#research#neuroscience
Visit https://lnkd.in/dRAvQB2Z to learn more about Fernando’s inspiration for investing in the life-saving and lifetime changing medulloblastoma research led by Child’s National Hospital.
